Following a full submission
AWMSG advice |
||
Status: Recommended with restrictions | ||
Pegfilgrastim (Neulasta®) is recommended as an option for restricted use within NHS Wales for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Its use should be restricted to patients where the risk of febrile neutropenia is high and where the risk of neutropenia from chemotherapy is likely to be prolonged (more than six days) or for patients with special circumstances e.g. geographical access, needle phobia. Pegfilgrastim (Neulasta®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
Medicine name | pegfilgrastim (Neulasta®) | |
Formulation | solution for injection | |
Reference number | 242 | |
Indication | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) |
|
Company | Amgen Ltd | |
BNF chapter | Nutrition & blood | |
Submission type | Full | |
Status | Recommended with restrictions | |
Advice number | 1508 | |
NMG meeting date | 16/07/2008 | |
AWMSG meeting date | 13/08/2008 | |
Ratification by Welsh Government | 29/09/2008 | |
Date of issue | 06/10/2008 |